Can a common anemia drug shield preemie brains from damage?
NCT ID NCT01378273
First seen May 20, 2026 · Last updated Jun 22, 2026 · Updated 3 times
Summary
This large Phase 3 trial tested whether giving erythropoietin (Epo) to extremely premature infants within 24 hours of birth could reduce death or severe neurodevelopmental problems. Over 900 babies born between 24 and 27 weeks of pregnancy were enrolled. The study compared Epo injections to a placebo and followed the children until they were about 2 years old.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTREME PREMATURITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
All Childrens Hospital
St. Petersburg, Florida, 33701, United States
-
Beth Israel Deaconess Hospital
Boston, Massachusetts, 02215, United States
-
Children's Hospital of Minnesota, MN
Minneapolis, Minnesota, 55404, United States
-
Children's Hospital of Minnesota, St. Paul
Saint Paul, Minnesota, 55102, United States
-
Children's Hospital of the University of Illinois
Chicago, Illinois, 60612, United States
-
Florida Hospital
Orlando, Florida, 32804, United States
-
Johns Hopkins
Baltimore, Maryland, 21224, United States
-
Maia Fareri Children's Hospital
Valhalla, New York, 10595, United States
-
Methodist Children's Hospital
San Antonio, Texas, 78229, United States
-
Prentice Women's Hospital
Chicago, Illinois, 60611, United States
-
South Miami Hospital
Miami, Florida, 33146, United States
-
University of Arkansas
Little Rock, Arkansas, 72202, United States
-
University of Florida
Gainesville, Florida, 32610, United States
-
University of Louisville
Louisville, Kentucky, 40202, United States
-
University of Minnesota Amplatz Children's Hospital
Minneapolis, Minnesota, 55455, United States
-
University of New Mexico Children's Hospital
Albuquerque, New Mexico, 87131, United States
-
University of Utah
Salt Lake City, Utah, 84108, United States
-
University of Washington
Seattle, Washington, 98195, United States
-
Wake Forest School of Medicine
Winston-Salem, North Carolina, 27157, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
erythropoietin (Epo)
What this could lead to
If it works, this could provide a safe therapy to improve brain development and reduce disability in extremely premature babies.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all preterm infants. Risks include potential side effects like blood clots or high red blood cell counts.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.